{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T10:27:08Z","timestamp":1781951228377,"version":"3.54.5"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.atherosclerosis.2023.03.009","type":"journal-article","created":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T21:59:38Z","timestamp":1678917578000},"page":"54-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Low-dose aspirin in the primary prevention of cardiovascular diseases: A retrospective, propensity score matched study"],"prefix":"10.1016","volume":"371","author":[{"given":"Seong Pyo","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiwon","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Hwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4432-4894","authenticated-orcid":false,"given":"Hyung-Jin","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2023.03.009_bib1","article-title":"The discovery of aspirin's antithrombotic effects","author":"Miner","year":"2007","journal-title":"Tex. Heart Inst. J."},{"key":"10.1016\/j.atherosclerosis.2023.03.009_bib2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.atherosclerosis.2023.03.009_bib3","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Baigent","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2023.03.009_bib4","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1805819","article-title":"ASPREE investigator group, effect of aspirin on cardiovascular events and bleeding in the healthy elderly","volume":"379","author":"McNeil","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2023.03.009_bib5","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.jacc.2019.03.009","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines","volume":"74","author":"Arnett","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2023.03.009_bib6","doi-asserted-by":"crossref","first-page":"836","DOI":"10.7326\/M16-0577","article-title":"Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive services task force recommendation statement","volume":"164","author":"Bibbins-Domingo","year":"2016","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.atherosclerosis.2023.03.009_bib7","first-page":"939","article-title":"2016 European Guidelines on cardiovascular disease prevention in clinical practice","volume":"69","author":"Piepoli","year":"2016","journal-title":"Rev. Esp. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2023.03.009_bib8","first-page":"214","article-title":"2018 Canadian cardiovascular society\/Canadian association of interventional cardiology focused update of the guidelines for the use of antiplatelet therapy","volume":"34","author":"Mehta","year":"2018","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2023.03.009_bib9","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1001\/jama.2022.5207","article-title":"Aspirin use to prevent cardiovascular disease: US preventive services task force recommendation statement","volume":"327","author":"Davidson","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2023.03.009_bib10","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1016\/j.jacc.2019.03.507","article-title":"ACC\/AHA versus ESC\/ESH on hypertension guidelines: JACC guideline comparison","volume":"73","author":"Bakris","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2023.03.009_bib11","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","article-title":"Others, Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial","volume":"351","author":"Hansson","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2023.03.009_bib12","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0140-6736(00)03539-X","article-title":"Collaborative group of the primary prevention Project, low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative group of the primary prevention Project","volume":"357","author":"de Gaetano","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2023.03.009_bib13","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","article-title":"Effects of aspirin for primary prevention in persons with diabetes mellitus","volume":"379","author":"Study Collaborative","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2023.03.009_bib14","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1161\/01.CIR.0000020190.45892.75","volume":"106","author":"Pearson","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2023.03.009_bib15","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1016\/S0140-6736(19)30541-0","article-title":"The rise and fall of aspirin in the primary prevention of cardiovascular disease","volume":"393","author":"Raber","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2023.03.009_bib16","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S0140-6736(18)31924-X","article-title":"Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial","volume":"392","author":"Gaziano","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2023.03.009_bib17","series-title":"Aspirin for the Primary Prevention of Cardiovascular Events: A Systematic Evidence Review for the U.S. Preventive Services Task Force","author":"Guirguis-Blake","year":"2016"},{"key":"10.1016\/j.atherosclerosis.2023.03.009_bib18","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1001\/archneur.57.3.326","article-title":"Aspirin for the primary prevention of stroke and other major vascular events: meta-analysis and hypotheses","volume":"57","author":"Hart","year":"2000","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.atherosclerosis.2023.03.009_bib19","first-page":"943","article-title":"Risk assessment and aspirin use in Asian and Western populations","volume":"6","author":"Gao","year":"2010","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.atherosclerosis.2023.03.009_bib20","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1001\/jama.295.3.306","article-title":"Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials","volume":"295","author":"Berger","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2023.03.009_bib21","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1016\/j.jacc.2019.03.501","article-title":"Aspirin for primary prevention of cardiovascular events","volume":"73","author":"Abdelaziz","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2023.03.009_bib22","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/0049-3848(86)90029-0","article-title":"Sex-related differences in the effects of aspirin on the interaction of platelets with subendothelium","volume":"44","author":"Escolar","year":"1986","journal-title":"Thromb. Res."},{"key":"10.1016\/j.atherosclerosis.2023.03.009_bib23","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0002-9149(01)01631-9","article-title":"Profile and prevalence of aspirin resistance in patients with cardiovascular disease","volume":"88","author":"Gum","year":"2001","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2023.03.009_bib24","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMoa050613","article-title":"A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women","volume":"352","author":"Ridker","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2023.03.009_bib25","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1001\/jama.295.12.1420","article-title":"Sex differences in platelet reactivity and response to low-dose aspirin therapy","volume":"295","author":"Becker","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2023.03.009_bib29","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1001\/jama.288.11.1388","article-title":"New evidence for stroke prevention: scientific review","volume":"288","author":"Straus","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2023.03.009_bib30","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1161\/STR.0000000000000046","volume":"45","author":"Meschia","year":"2014","journal-title":"Stroke"},{"key":"10.1016\/j.atherosclerosis.2023.03.009_bib31","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.amjmed.2011.01.018","article-title":"Effect of aspirin on mortality in the primary prevention of cardiovascular disease","volume":"124","author":"Raju","year":"2011","journal-title":"Am. J. Med."},{"key":"10.1016\/j.atherosclerosis.2023.03.009_bib32","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1016\/j.amjcard.2011.02.325","article-title":"Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin","volume":"107","author":"Bartolucci","year":"2011","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2023.03.009_bib33","doi-asserted-by":"crossref","first-page":"826","DOI":"10.7326\/M15-2112","article-title":"Bleeding risks with aspirin use for primary prevention in adults: a systematic review for the U.s. preventive services task force","volume":"164","author":"Whitlock","year":"2016","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.atherosclerosis.2023.03.009_bib34","article-title":"Pros and cons of aspirin for the primary prevention of cardiovascular events: a secondary study of trial sequential analysis","volume":"11","author":"Zhao","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.atherosclerosis.2023.03.009_bib35","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.3892\/ol.2020.11817","article-title":"Effects of aspirin on the gastrointestinal tract: Pros vs. cons","volume":"20","author":"Li","year":"2020","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.atherosclerosis.2023.03.009_bib36","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1002\/cpt.1210","article-title":"Using real-world data to extrapolate evidence from randomized controlled trials","volume":"105","author":"Wang","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.atherosclerosis.2023.03.009_bib37","doi-asserted-by":"crossref","first-page":"vii54","DOI":"10.1093\/rheumatology\/key109","article-title":"Randomized controlled trials and real-world data: differences and similarities to untangle literature data","volume":"57","author":"Monti","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.atherosclerosis.2023.03.009_bib38","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1001\/jama.2022.3337","article-title":"Aspirin use to prevent cardiovascular disease and colorectal cancer: updated evidence report and systematic review for the US preventive services task force","volume":"327","author":"Guirguis-Blake","year":"2022","journal-title":"JAMA"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915023001119?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915023001119?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:51:22Z","timestamp":1758156682000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915023001119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":35,"alternative-id":["S0021915023001119"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2023.03.009","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low-dose aspirin in the primary prevention of cardiovascular diseases: A retrospective, propensity score matched study","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2023.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}